CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy

Show full item record



Permalink

http://hdl.handle.net/10138/309911

Citation

Zafar , S , Sorsa , S , Siurala , M , Hemminki , O , Havunen , R , Cervera-Carrascon , V , Santos , J M , Wang , H , Lieber , A , De Gruijl , T , Kanerva , A & Hemminki , A 2018 , ' CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy ' , OncoImmunology , vol. 7 , no. 10 , 1490856 . https://doi.org/10.1080/2162402X.2018.1490856

Title: CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
Author: Zafar, Sadia; Sorsa, Suvi; Siurala, Mikko; Hemminki, Otto; Havunen, Riikka; Cervera-Carrascon, Victor; Santos, Joao Manuel; Wang, Hongjie; Lieber, Andre; De Gruijl, Tanja; Kanerva, Anna; Hemminki, Akseli
Contributor: University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Department of Oncology
University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2018
Language: eng
Number of pages: 10
Belongs to series: OncoImmunology
ISSN: 2162-402X
URI: http://hdl.handle.net/10138/309911
Abstract: Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer immunotherapy in general is the immunosuppressive tumor microenvironment, which hampers the maturation and activation of DCs. Therefore, human clinical outcomes with DC therapy alone have been disappointing. In this study, we use fully serotype 3 oncolytic adenovirus Ad3-hTERT-CMV-hCD40L, expressing human CD40L, to modulate the tumor microenvironment with subsequently improved function of DCs. We evaluated the synergistic effects of Ad3-hTERT-CMV-hCD40L and DCs in the presence of human peripheral blood mononuclear cells ex vivo and in vivo. Tumors treated with Ad3-hTERT-CMV-hCD40L and DCs featured greater antitumor effect compared with unarmed virus or either treatment alone. 100% of humanized mice survived to the end of the experiment, while mice in all other groups died by day 88. Moreover, adenovirally-delivered CD40L induced activation of DCs, leading to induction of Th1 immune responses. These results support clinical trials with Ad3-hTERT-CMV-hCD40L in patients receiving DC therapy.
Subject: Dendritic cells
T-cells
oncolytic adenovirus
Ad3
CD40L
INTERFERON-GAMMA GENE
ADVANCED SOLID TUMORS
CANCER-PATIENTS
IMMUNE-RESPONSE
ANTITUMOR IMMUNITY
GROWTH-FACTOR
PHASE-I
METASTATIC MELANOMA
POOR-PROGNOSIS
BREAST-CANCER
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
CD40L_coding_oncolytic_adenovirus_allows.pdf 1016.Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record